S214 • OFID 2017:4 (Suppl 1) • Poster Abstracts Methods. Setting—Urban Ryan White funded clinic in Columbia, SC providing care to about 2200 PLWH. A retrospective chart review was performed on a sample of patients ≥40 years old. Patients were eligible if they did not have a known diagnosis of ASCVD, had ≥ 3 visits in the last 3 years, and at least 1 visit in the past 12 months. Data regarding demographics, comorbidities, lab values, medications, and recent blood pressures were abstracted. Data were collected on assessment and intervention for smoking, weight loss, diet, and exercise. Objectives of this study were to: (1) deter- mine the prevalence of ASCVD risk factors among patients without known ASCVD; (2) estimate the proportion of patients who received appropriate pharmacologic and lifestyle interventions. Results. Charts were reviewed in random order until 100 charts had the required variables to calculate the 10-year ASCVD risk (Figure 1). Tese complete charts were similar in demographic characteristics to the clinic population. Of the complete charts, 66% met BMI criteria for being obese or overweight; but < 30% of these patients had documentation of the diagnosis, or received appropriate intervention for diet, exer- cise, or weight loss. HTN was diagnosed in 42% of patients, and 52% of these were adequately controlled. An additional 9% met criteria for HTN but did not carry the diagnosis. Documented diagnosis of DM was surprisingly low at <5%. Nurses assessed smoking in 100% of patients, and the majority of smokers received an intervention. Based on current guidelines, less than 25% of eligible patients were prescribed a statin (Figure 2). To our concern, none of the patients with LDL ≥190 mg/dL or DM had evidence of statin therapy. Conclusion. Although > 85% of clinic patients have an undetectable HIV viral load, there were multiple missed opportunities for primary prevention of cardiovas- cular disease, including interventions for smoking cessation, diet and exercise, and guideline based anti-HTN and statin therapy. Figure 1: Disclosures. A. Jones, Proctor & Gamble: Stock, Dividend. CVS Health Corp: Stock, Dividend. Johnson & Johnson: Stock, Dividend. Baxter Inc.: Stock, Dividend. Becton-Dickinson: Stock, Dividend. United Health Group: Stock, Dividend 573. A Comparative Analysis of Cardiovascular Risk in HIV Sero-positive and Sero-negative Pre-menopausal Women Ambreen Raza, MD 1 and Srikrishna Varun Malayala, MD MPH FACP 2 ; 1 Infectious Diseases, Cooper University, Camden, New Jersey, 2 Hospital Medicine, Jeanes Hospital/Temple University Health system, Philadelphia, Pennsylvania Session: 65. HIV: Cardiovascular Disease, Lipids, Diabetes Thursday, October 5, 2017: 12:30 PM Background. HIV infection has been associated with an increased risk of car- diovascular disease (CVD), stroke, and subclinical atherosclerosis in women. HIV- positive pre-menopausal women tend to lose the cardio-protective efect of estrogen and these women should be more vigilant in reducing their risk for developing CVD. Our study intends to assess the cardiovascular risk in the HIV-positive pre-menopau- sal women over the last 16 years (1999-2014) using a national wide sample. Methods. Tis study is a cross-sectional study using the National Health and Nutrition Examination Survey (NHANES) datasets from 1999 to 2014. Te 10-year Framingham risk score for developing CAD was calculated for the HIV-positive and HIV-negative pre-menopausal women. Te individual risk factors contributing to CAD including blood pressure, hemoglobin A1c, c-reactive protein (CRP), smoking status, cholesterol level, family history of CVD were compared. Te populations’ intent to reduce their risk (exercise, diet modifcation and use of medications) and their doc- tor’s advice to reduce the risk (counseling on diet, exercise and weight) were also ana- lyzed. SPSS v.19 was used for analysis and p-value < 0.05 was considered signifcant. Results. Out of the available sample of 82,091 people, 9635 women (11.7%) met the inclusion criteria (pre-menopausal women, 18 to 55 year old, no prior history of CAD, no missing data and tested for HIV). Among them, 25 women were HIV seropositive (0.25%). Tough there was no signifcant diference in the systolic and diastolic blood pressure, HbA1c, CRP, HDL or total cholesterol (P > 0.05); the mean Framingham risk score in pre-menopausal HIV-positive women (M = 2.12, SD = 2.73) was signifcantly higher than the HIV-negative women (M = 0.95, SD = 1.94); P <0.01. Neither did majority of the HIV-positive women intend to decrease their cardiovascu- lar risk nor did their health care providers advice them to do so. Conclusion. Tis study shows that the risk of developing CVD in pre-menopau- sal women seems to be higher from the traditional risk factors itself. While HIV is now independent risk factor for developing CVD in women, more focus should be on reducing the risk from traditional methods like smoking cessation, diet and life style modifcation, blood pressure, diabetes and cholesterol and management. Disclosures. All authors: No reported disclosures.  574. Statin Utilization Among Human-Immunodeficiency Virus (HIV)-Infected Individuals Based on the 2013 American College of Cardiology and American Heart Association (ACC/AHA) Blood Cholesterol Guideline Lemuel Non, MD 1 ; Naureen Ali, MBBS, MD 2 ; Rachel Presti, MD, PhD 1 ; William Powderly, MD 3 and Gerome Escota, MD 4 ; 1 Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, Saint Louis, Missouri, 2 Internal Medicine, UIC/ Advocate Christ Internal Medicine Residency, Oak Lawn, Illinois, 3 Division of Infectious Diseases, Washington University, St. Louis, Missouri, 4 Division of Infectious Diseases, Washington University in St. Louis, St. Louis, Missouri Session: 65. HIV: Cardiovascular Disease, Lipids, Diabetes Thursday, October 5, 2017: 12:30 PM Background. Tere are limited data on statin utilization among HIV+ individuals in real-world settings using the new 2013 ACC/AHA blood cholesterol guideline. We aimed to determine the proportion of appropriate statin use based on this guideline in a large urban outpatient center. Methods. Chart review of 1087 HIV+ patients 40 years and over from the Washington University Virology Clinic was done from January 1 to December 31, 2015. Patients were classifed according to the 4 statin beneft groups from the guide- line: (1) those with clinical atherosclerotic cardiovascular disease (ASCVD); (2) those with primary hyperlipidemia (LDL-C ≥ 190 mg/dL); (3) individuals 40 to 75 years of age with diabetes and an LDL 70 to 189 mg/dL without ASCVD; and (4) those 40 to 75 years of age without ASCVD or diabetes, with LDL 70 to 189 mg/dL, and with a 10-year ASCVD risk of ≥ 7.5%. Factors that may infuence receipt of statin were ana- lyzed using the chi-square test, t-test, or the Wilcoxon rank-sum test when applicable. Results. Te median age of patients was 51 years and the majority were male (71%), black (67%), receiving antiretroviral therapy (98%), had HIV RNA ≤ 20 copies/ ml (87%) and median CD4 count of 523 cells/µL. Overall, 450 (41%) patients had an indication for statin use, with the majority classifed under group 4. However, only 160 (36%) were on statins, of whom 89% were on appropriate doses. Te percentages of patients on statins were only 36%, 44%, 49%, and 30% for groups 1, 2, 3, and 4, respectively. Tere was no signifcant diference between those who were and were not on statins in terms of CD4 count and pill burden. Te rates of ritonavir, cobicistat, and efavirenz use were also similar between the two groups. In group 4, however, those who had viral suppression were more likely to be prescribed a statin compared with those who had no viral suppression (95% vs. 87%, P = 0.031). Conclusion. Two-thirds of our patients were not prescribed statins despite a strong indication for it based on the new guideline. Our fnding stresses the critical